|
|||||||||||
 |
|||||||||||
|
|||||||||||
Top Stories
Immunize.org Website and Clinical Resources
Featured Resources
Notable Publications
Upcoming Events
Immunize.org posts its up-to-date 2025–26 suite of influenza vaccination resources
Immunize.org completed the annual review of our entire suite of influenza clinical resources for the 2025–26 season. All materials have a new date in the footnote to indicate they were reviewed and are current for the 2025–26 season, whether or not changes were necessary. These resources include:
Related Links
Immunize.org posted Spanish translations of the two current pneumococcal VISs that were updated by CDC on May 29, 2025.
  To locate VIS translations for a particular vaccine, click on “Vaccines & VISs” at Immunize.org, click on “VISs,” and then select a specific vaccine. Scrolling down the resulting page, you will see the current English VIS (the official federal version), followed by a list of translations of the current English version. Where applicable, current translations are followed by a list of translations of past English versions that are still usable because they are the most recent translations available in those languages. When a patient is given any VIS translation, they should also receive the current official VIS, which is in English. Additional tips on using VISs appear at the bottom of the web page. Check the version date of your inventory of VIS translations. Discard translations of previous versions as translations of current versions become available. Related Links
Immunize.org’s team of experts reviewed and updated all questions and answers in Ask the Experts: Zoster (Shingles). There have been no changes to federal recommendations for the use of recombinant zoster vaccine (RZV, Shingrix, GSK) since the previous update in 2022. Immunize.org’s Ask the Experts main page leads you to 30 web pages on various topics with more than 1,300 common or challenging questions and answers about vaccines and their administration. Immunize.org’s team of experts includes Kelly L. Moore, MD, MPH (team lead); Carolyn B. Bridges, MD, FACP; Iyabode Beysolow, MD, MPH; and Jane Zucker, MD, MSC. Related Links
Routine hepatitis B birth dose policies protect babies. Immunize.org’s Hepatitis B Birth Dose Honor Roll recognizes 593 institutions, including three new honorees.
Hepatitis B (HepB) vaccination is extremely effective during infancy, protecting about 98% of healthy, term infants. Transmission of hepatitis B virus (HBV) during infancy results in chronic, lifelong infection for about 9 in 10 babies, with one in four of them going on to develop cirrhosis or liver cancer in adulthood. Vaccination and use of hepatitis B immune globulin (HBIG) for infants born to HBV test-positive mothers (and mothers of unknown status) reduces the risk of HBV transmission by 94%; vaccination alone, given on the day of birth, reduces the risk by 75%.
Please join us in recognizing this honoree with a decade of sustained excellence:
The Honor Roll includes birthing institutions from 50 states, the District of Columbia, American Samoa, Guam, Puerto Rico, Northern Mariana Islands, and U.S. military hospitals overseas. The Honor Roll is a key part of Immunize.org’s initiative urging U.S. hospitals to Give Birth to the End of Hep B. Hospitals and birthing centers are recognized for attaining high coverage for hepatitis B vaccine at birth and meeting additional criteria. The How to Apply web page provides information on the criteria for inclusion in the Hepatitis B Birth Dose Honor Role and the application form.
National Hispanic Heritage Month runs from September 15 to October 15; Immunize.org’s Spanish language resources support your Spanish-speaking patients National Hispanic Heritage Month, observed from September 15 to October 15, celebrates the histories, cultures, and contributions of Americans whose ancestors came from Spain and elsewhere in the Americas.
Happy Mexican Independence Day, September 16! Here’s an orientation to vaccination information and advocacy in Mexico.
¡Viva México! September 16 is the 214th anniversary of Mexico’s independence. We celebrate our neighbors by sharing select Mexican resources for vaccination information and advocacy.
 Helpful resources:
Best wishes to all our friends delivering vaccinations to the people of Mexico! 
“If a Mother Received Abrysvo RSV Vaccine During Pregnancy, Does the Infant Need RSV Preventive Antibody?” Watch the 1-minute answer, part of the Ask the Experts Video Series on YouTube.
This week, our featured episode from the Ask the Experts Video Series is titled If a Mother Received Abrysvo RSV Vaccine During Pregnancy, Does the Infant Need RSV Preventive Antibody? For infants younger than age 8 months, the recommendation is to only administer RSV preventive antibody product if the mother was not vaccinated, or not effectively vaccinated, with Abrysvo (Pfizer) brand of RSV vaccine during pregnancy. Maternal vaccination should be considered ineffective if, for example, the infant was born less than 14 days after maternal vaccination or if Arexvy (GSK) brand of RSV vaccine was given during pregnancy. Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise.
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is a selection of our recent citations.
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
Spotlight on the website: "Translations" web page simplifies access to our resources in 48 languages
Immunize.org offers translations of VISs and popular Patient Handouts. Our Translations web page provides quick access to every translated resource on the Immunize.org website. Translations of one or more documents are available in 48 languages. This "Translations" page is accessible from two menus at the top of each page: either the “Vaccines & VISs” or “Clinical Resources” menu. The direct link is www.immunize.org/translations.
Patients benefit from having vaccine information in their preferred language. Immunize.org's "Translations" page makes it easier for you to meet their needs. Back to top Recap: Immunize.org’s commitment to sharing clinical vaccination guidance based on the best available scientific evidence The recent changes to the membership of ACIP and resignation of respected scientific leaders at CDC have raised serious concerns across public health and healthcare communities. Information shared by the departing CDC leaders has raised doubts about the scientific validity of vaccine policies contemplated by the current administration. In addition, we observed the June ACIP vote against the use of thimerosal-containing influenza vaccines, a decision made without following the standard rigorous review of available data or the structured evidence-to-recommendations framework. In response, professional medical societies (e.g., American Academy of Pediatrics, American College of Obstetricians and Gynecologists) have begun to issue vaccination guidance that differs from new CDC guidance. Vaccination providers and educators who depend on Immunize.org resources should understand how we are approaching this unprecedented situation. Recap: Immunize.org updates “Standing Orders for Administering Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy” to reference both preventive antibody options for infant RSV prevention Immunize.org updated its Standing Orders for Administering Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy, to note the options to use nirsevimab (Beyfortus, Sanofi) or clesrovimab (Enflonsia, Merck) for infant RSV protection if the mother was not effectively vaccinated during her pregnancy. Back to topRecap: Immunize.org updates “Meningococcal B Vaccine Recommendations by Age and Risk Factor” to include both pentavalent MenABCWY vaccine options Immunize.org updated Meningococcal B Vaccine Recommendations by Age and Risk Factor to add the second pentavalent MenABCWY vaccine (Penmenvy, GSK ) in addition to Penbraya (Pfizer). Immunize.org recently updated its popular resource for healthcare professionals titled Before You Vaccinate Adults, Consider Their “H-A-L-O”! H-A-L-O refers to four factors:
Edits incorporate the age 50 threshold for adults with risk factors to receive RSV vaccine and referral to current recommendations for COVID-19 vaccine. Association of Immunization Managers offers handout compiling a variety of useful influenza vaccination resources
The Association of Immunization Managers (AIM) posted Connecting the Dots: Influenza Vaccinations, a one-page resource guide designed to support influenza vaccination efforts. It conveniently lists several tools, helping users quickly access what they need. It is organized into three categories: health education, health communication, and program planning. Connecting the Dots will be updated monthly. New web page from CHOP's Vaccine Education Center provides links to the latest science-based vaccine recommendations
Children's Hospital of Philadelphia's Vaccine Education Center launched a new web page, Locating the Latest Science-Based Vaccine Recommendations, to assist in staying abreast of the latest science-based recommendations. Needle anxiety is common at any age. Use Immunize.org’s clinical resources to offer a positive vaccination experience.
In Clinical Resources: Improving the Vaccination Experience, Immunize.org provides print and video tools to create a positive vaccination experience and ease injection anxiety in children and adults. Links to additional resources from trusted partner organizations are also provided.
Related Link
Help Immunize.org reach more vaccinators through your social media networks. Follow us and share our posts on Facebook, Instagram, and LinkedIn!
Immunize.org offers a social media program to highlight our educational resources for a widespread audience of vaccinators. Our social media channels now feature our most popular printable resources and Ask the Experts questions, as well as announcements important to frontline vaccinators. Please view and share our newest feature, the Ask the Experts Video Series. Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:
“Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in a Child with No Known Exposure—San Francisco, California, December 2024–January 2025” published in MMWR
CDC published Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in a Child with No Known Exposure—San Francisco, California, December 2024–January 2025 on September 4 in MMWR. A portion of the summary appears below.
Today, virtual: Register for Immunize.org Website Office Hours. Join a 30-minute discussion about the VIS web section on September 10 at 4:00 p.m. (ET) or September 11 at 12:00 p.m. (ET). Recorded sessions archived.
To learn simple tips and tricks for using our website efficiently, please register for our next set of Website Office Hours on Wednesday, September 10, at 4:00 p.m. (ET) or Thursday, September 11, at 12:00 p.m. (ET). The same content will be covered in both sessions. Register today for Immunize.org Website Office Hours (content is the same for both): The archive of previous Website Office Hours content is posted at Immunize.org’s "Webinars & Videos" page. Mark your calendar for future Immunize.org Website Office Hours. Virtual: Watch CDC’s webinar “Clinician Update on Measles Cases and Outbreaks in the United States” on September 11 at 2:00 p.m. (ET); CE credit offered
CDC will host a 1-hour Clinician Outreach and Communication Activity (COCA) call titled Clinician Update on Measles Cases and Outbreaks in the United States at 2:00 p.m. (ET) on September 11. Presenters will discuss the current epidemiology of measles in the United States and address common clinical questions about preventing, identifying, and testing for measles. Presenters will summarize MMR vaccination recommendations and considerations. Virtual: North Dakota State University Center for Immunization Research and Education hosts webinar titled “Science to Practice: Protecting Children from Respiratory Viruses in 2025–2026” on September 16 at 1:00 p.m. (ET); CE credit offered
The North Dakota State University Center for Immunization Research and Education will host a webinar titled Science to Practice: Protecting Children from Respiratory Viruses in 2025–2026, from 1:00 p.m. (ET) on September 16. This webinar will explore the latest trends in RSV, influenza, and COVID-19 in children, highlighting both established patterns and emerging threats. Virtual: September 18–19 ACIP meeting announced; discussion and possible votes on COVID-19, hepatitis B, MMRV, and RSV vaccines planned
CDC is scheduled to convene the ACIP on September 18–19. Based on a notice in the Federal Register, the meeting will discuss and potentially vote on COVID-19, hepatitis B, and MMRV vaccines and RSV preventive antibody products. An agenda has not yet been posted. Related Links
For more upcoming events, visit our Calendar of Events. |
|||||||||||
|
